Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Food and Drug Administration (FDA)
Biotech
After delay, Coya receives FDA go-ahead for phase 2 ALS trial
The agency previously alerted Coya that it would miss the July 30 deadline for a decision on the IND application due to limited resources.
Darren Incorvaia
Aug 25, 2025 11:04am
FDA draft recommends all cancer trials collect OS data
Aug 20, 2025 10:59am
Regenxbio's Hunter gene therapy latest to face FDA delay
Aug 19, 2025 10:30am
Another biotech hit with FDA delay for ALS asset
Aug 18, 2025 11:01am
FDA delays Omeros' 2nd attempt at transplant drug’s approval
Aug 15, 2025 5:55am
Big Pharma-backed program seeks future beyond animal testing
Aug 1, 2025 5:00pm
